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Abstract Maltose-binding protein (MBP) from Escherichia
coli has been shown to be a good substrate for protein
engineering leading to altered binding (Marvin and Hellinga,
Proc Natl Acad Sci U S A 98:4955–4960, 2001a)a n d
increased affinity (Marvin and Hellinga, Nat Struct Biol
8:795–798, 2001b; Telmer and Shilton, J Biol Chem
278:34555–34567, 2003). It is also used in recombinant
protein expression as both an affinity tag and a solubility tag.
We isolated mutations in MBP that enhance binding to
maltodextrins 1.3 to 15-fold, using random mutagenesis
followed by screening for enhanced yield in a microplate-
based affinity purification. We tested the mutations for their
ability to enhance the yield of a fusion protein that binds
poorly to immobilized amylose and their ability to enhance
the solubility of one or more aggregation-prone recombinant
proteins. We also measured dissociation constants of the
mutant MBPs that retain the solubility-enhancing properties
of MBP and combined two of the mutations to produce an
MBP with a dissociation constant 10-fold tighter than wild-
type MBP. Some of the mutations we obtained can be
rationalized based on the previous work, while others indicate
new ways in which the function of MBP can be modified.
Keywords Maltose-binding protein.Periplasmic binding
proteins.Altered affinity.Mutational analysis.
Recombinant fusion proteins.Solubility enhancement
The Escherichia coli maltodextrin-binding protein (MBP)
is a member of the periplasmic binding protein family and
functions in the transport of maltodextrins. The role of
MBP is to bind maltodextrins at the outer membrane porin
LamB and release them to the MalEFK transport apparatus
in the inner membrane. A high affinity is required when in
position at the outer membrane to bind maltodextrins, but
the sugar must be released at the inner membrane when it
docks with the transport apparatus. It accomplishes this in
part by having two conformations, the closed form which
favors binding and the open form which favors release. In
addition, MBP acts as a sensor for maltodextrins in the
chemotactic system, interacting with the signal transduction
protein Tar to regulate motility. The affinity characteristics
of MBP for maltodextrins in vivo have been selected to
optimize these functions.
MBP isalsoa usefultag for the expression and purification
ofrecombinantproteinsinthreeways:improvingtranslational
expression, providing an affinity purification strategy, and
enhancing the solubility of many refractory proteins. Micro-
bialexpressionsystemssuchasthosedevelopedforE. coli are
often the first choice for preparing large amounts of
recombinant proteins due to their low cost and high yield.
To facilitate the expression and purification of a target
protein, one method that is in common use is to fuse a tag to
the protein. A good tag has properties that facilitate high-
level translational expression when fused to the target
protein, as well as providing a simple one-step affinity
purification that allows the target protein to be purified from
the expression milieu. MBP is commonly used as a tag for
expression and purification of foreign proteins produced in
E. coli. Fusion of the C terminus of MBP to the N terminus
of a target protein facilitates the expression of the fusion
proteininE. coli. MBP and MBP fusions can be purified in a
single step by binding to a chromatography matrix containing
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such as amylose, starch or other maltodextrins. MBP is also
useful as a “solubility tag.” Proteins that are soluble in their
nativehostaresometimesinsolublewhenexpressedinE. coli.
For many of these proteins, fusion to MBP renders them
soluble (Kapust and Waugh 1999).
MBP has previously been engineered for changes in
binding affinity and specificity. The Kd of MBP for maltose
and maltotriose in vitro is about 2 and 0.4 µM, respectively
(Miller et al. 1983; Telmer and Shilton 2003). The X-ray
crystal structure of MBP shows that MBP consists of two
domains, with a cleft between the domains where the
polysaccharide binds (Duan and Quiocho 2002; Sharff et al.
1992; Spurlino et al. 1991). The domain that contains the N
terminus is named domain I, and the domain that contains
the C terminus is named domain II. Three loops cross
between the two domains to form a hinge. Researchers have
used the structure of MBP to make directed mutations in
order to alter the binding properties of MBP. Using directed
mutagenesis based on the structure, MBP has been
engineered to bind zinc (Marvin and Hellinga 2001a). In
addition, two reports have described using the structure to
make directed mutations to the region behind the hinge that
increases the affinity of MBP for maltose and maltotriose
(Marvin and Hellinga 2001b; Telmer and Shilton 2003).
However, the mutations made using this approach can
decrease MBP’s ability to enhance the solubility of proteins
to which it is fused, thus reducing its utility as a tag
(Nallamsetty and Waugh 2007).
In this study, we explored the possibility that there might
exist mutations in MBP that alter its conformation and/or its
affinity for maltodextrins without compromising its solubility-
enhancing properties, either by subtle changes in the hydro-
phobic core of the protein or by surface changes that do not
compromise its folding or solubility. We set out to identify such
mutations by random mutagenesis and screening for mutants
that out-performed wild-type MBP2 in an affinity purification.
Materials and methods
Materials Restriction enzymes, β-agarase, DNA poly-
merases, T4 ligase, antarctic phosphatase, Litmus 38, the
pMAL Protein Fusion and Purification System including
pMAL-c2X, pMAL-c2G, and pMAL-c4X, the USER
Friendly Cloning kit, amylose resin, anti-MBP monoclonal
antibody linked to horseradish peroxidase, and synthetic
oligonucleotides were obtained from New England Biolabs.
The nuclease Benzonase from Serratia marcescens was
purified as an MBP fusion protein and separated from MBP
by digestion with factor Xa protease, using the pMAL
system (data not shown). Whatman Unifilter 800 micro-
plates with filter bottoms and Immulon 2HB microplates
were purchased from VWR. The MinElute DNA Extraction
and QIAquick Spin kits were purchased from Qiagen. The
detergent MEGA 10 was purchased from Dojindo. Hen egg
white lysozyme and Coomassie brilliant blue R were
purchased from Sigma–Aldrich. Disposable polypropylene
columns (#732-6008) were purchased from BioRad; 10–
20% gradient gels were purchased from either Daiichi or
Invitrogen/Novex.
Strains and plasmids Host strains TB1, ER1992, ER2502,
ER2984, NEB 5-alpha, NEB Turbo, and NEB Express were
obtained from New England Biolabs. The source of the
Bacillus circulans chitin binding domain (CBD) was
pMB50, kindly provided by M. Xu (see Supplemental
data). The construction of the pMAL derivatives pSN1578
and pIH1684 is described in the supplemental data. The
pMAL-DHFR and pMAL-GAPDH plasmids were con-
structed using a protocol similar to ligation-independent
cloning (Aslanidis and de Jong 1990), except in this case,
the overhangs created were short and still require ligase to
produce a transformable plasmid (see Supplemental data).
The DHFR and GAPDH regions from the resulting
plasmids were then transferred into other pMAL derivatives
as AvaI, SbfI or AvaI, HindIII fragments.
PCR mutagenesis Random PCR mutagenesis was carried
out as described in (Fromant et al. 1995). Briefly, four
reactions were carried out, each with three of the four
nucleotides at a concentration of 0.2 mM and the fourth
nucleotide at 0.5 mM. PCR was performed using Taq
polymerase in the presence of 6 mM MgSO4. For the first
library, the malE gene was amplified with the primers 5′
GGAGACAUGAATTCAATGAAAATCGAAGAA and 5′
GGGAAAGUAAGCTTAATCCTTCCCTCGATC, using
pMAL-c2X as a template. PCR fragments were cloned
into linearized pNEB208A using the USER Friendly
Cloning Kit, following the manufacturer’s instructions.
For the second library, the malE gene was amplified with
the primers 5′CACGAGCAATTGACCAACAAGGAC and
5′GATCGAGAGCTCGAATTAGTCTGC. Both the PCR
product and pIH1684 were cut with MfeI and SacI and gel
purified, and the two fragments were ligated. Transformants
from each library were grown overnight in 0.9 mL LB + 10
uM IPTG and 100 ug/mL ampicillin and then lysed by
adding 0.1 mL of a detergent/lysozyme/nuclease solution,
giving a final concentration of 50 mM Tris–Cl pH 8.0,
50 mM NaCl, 0.2 mM EDTA, 0.2 mg/mL lysozyme, 0.3%
MEGA-10, and 20 U/mL of Benzonase (to reduce
viscosity; modified Kunitz units (Friedhoff et al. 1994))
and incubating for 2 min at room temperature.
Screening MBP mutants by affinity purification Of the
extracts prepared, 0.7 mL, as described above, was applied
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microplate, and each well was washed with 2 mL of 20 mM
Tris–Cl, 0.2 M NaCl, 1 mM EDTA, pH 7.4 (column buffer,
CB) containing 0.2% Tween 20, then with 2 mL of CB
without Tween 20, and finally with 1 mL of 10 mM sodium
phosphate, 0.2 M NaCl, 1 mM EDTA, pH 7.2. The protein
bound to the amylose resin was then eluted with 0.2 mL of
10 mM maltose, 10 mM sodium phosphate, 0.2 M NaCl,
1 mM EDTA, pH 7.2.
The eluate was transferred to an Immulon 2HB microplate
and incubated overnight at 4°C. The microplate wells were
then emptied, washed twice with 20 mM Tris–Cl, 150 mM
NaCl, pH 7.5 (TBST), then blocked with 0.36 mLTBST+3%
bovineserumalbuminfor1hat37°C.Thewells werewashed
twice with TBST, then 0.2 mL of a 1:2,000 dilution of anti-
MBP monoclonal antibody linked to horse radish peroxidase
in TBST+3% bovine serum albumin was added to each well
and the plate incubated at 37°C for 1 h. The wells were
emptied and then washed three times with TBST. The wells
were developed with 0.01% o-phenylenediamine, 0.003%
hydrogen peroxide in water. The detection reaction was
stopped by adding 0.025 mL 4 M H2SO4, and wells were
assayed spectrophotometrically at 490 nm. Cells were
recovered from samples corresponding to lysates that
showed higher binding and elution as compared to wild-
type MBP. These candidates were grown and retested to
confirm the higher binding and elution. A list of the
mutations is given in Table S1.
Subcloning and separation of mutations For the first library,
the genes for candidate MBP mutants were processed with
PCR from pNEB208A using the primers 5′ GACTCATAT
GAAAATCGAAGAAGGTAAACTGGTAATCTGGAT
TAACGGC and 5′ ATATAAGCTTTCACCTTCCCTC
GATCCCGAGGT. The PCR fragment was cut with NdeI
and HindIII and ligated into the pMAL derivative pIH1684
cut with the same enzymes. The second library was
constructed directly in pIH1684, so testing proceeded
without needing to subclone. Of the 25 mutants obtained
in the screen, ten had silent mutations in addition to one or
more missense mutations; the silent mutations were ignored
for this analysis. Five were identical in sequence to another
mutant, presumed to be siblings, and dropped. Nine had a
single missense mutation. The remaining 11 had from two
to five missense mutations. The mutations in the multiple
mutants were reconstructed separately by either subcloning,
when appropriate sites were available, or four primer
mutagenesis as described in Guan and Kumar 2005. The
PCR fragments produced were ligated into pIH1684.
Small-scale affinity purification of MBP and MBP fusions A
200-mL culture of each variant of MBP2 to be tested was
grown in LB+0.1% glucose and 100 µg/mL ampicillin to
early log phase, then induced by addition of IPTG to a final
concentration of 0.3 mM. The cells were harvested after 2 h
and resuspended in 5 mL CB, sonicated, and clarified at
9,000×g for 30 min. A 1.6-mL sample of the supernatant
was diluted to 8 mL with CB and applied to a 1-mL
amylose column. The column was washed with 16 mL CB
and eluted with 4 mL of CB+10 mM maltose. The protein
in the eluate was quantitated by spectrophotometry at
280 nm (A280 of 1 corresponds to 0.66 mg/mL). Values
for wild-type (included in all experiments as a control) are
the average of 19 experiments, and values for A312V
(included as an additional control in most experiments) are
the average of 16 experiments; all others are the average of
2–8 experiments and are expressed as % yield relative to
wild-type in the same experiment, then normalized to the
overall wild-type average.
Solubility enhancement of MBP fusions A 10-mL culture of
NEB Express containing the pMAL-DHFR or pMAL-
GAPDH derivative was grown to 2×10
8 cells/mL in LB+
0.1% glucose and 100 µg/mL ampicillin, induced with
0.3 mM IPTG, incubated for an additional 2 h, then cells
were harvested by centrifugation at 3,000×g in a microfuge.
Each pellet was resuspended in 1 mL of CB and lysed by
sonication. The lysate was centrifuged for 2 m at 14,000×g,
and the supernatant was removed and designated the
soluble fraction. The pellet was resupended in 1 mL of
the same buffer and designated the insoluble fraction. A
sample (4 uL) of each fraction was run on SDS–PAGE
for each strain, the gels were dried and scanned, and the
amount of MBP fusion protein in each lane was
quantitated using ImageJ (Abramoff et al. 2004). Results
are expressed as a ratio of soluble MBP fusion protein to
total MBP fusion protein present in the soluble and
insoluble lanes.
Determination of dissociation constants Kd measurements
were made by measuring maltose-induced fluorescence
quenching (Miller et al. 1983) using a Perkin–Elmer LS50B
luminescence spectrophotometer. All measurements were
carried out at room temperature (25–26°C), at a protein
concentration of 15 µg/mL (0.32 µM) and an excitation
wavelength of 290 nm. Emission scans were done with
excitation slit width of 2.5 nm and an emission slit width
of 5.0 nm. Titrations with maltose or maltotriose were
carried out with excitation a n de m i s s i o ns l i tw i d t h so f
5.0 nm, and an emission wavelength of 330 and/or
350 nm, depending on the mutant (see “Results”). The
data were plotted as percent quenched vs. input maltose/
maltotriose concentration, and the dissociation constant
determined by a curve-fit using the equilibrium binding
equation in Miller et al. 1983 and the software KaleidaGraph
4 (Synergy Software).
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MBP mutations that affect affinity purification We undertook
the present study to see if we could identify mutations in
MBP that would increase its ability to bind and elute from
an amylose affinity resin. We hoped that by screening
random mutants for this property, we might identify
mutations that affect the affinity without altering the
properties that make MBP a useful affinity tag, most
importantly its ability to enhance the solubility of proteins
that tend to be insoluble when expressed in E. coli. Wild-
type MBP of E. coli is made as a precursor with an N-
terminal signal peptide and secreted into the periplasm
where the signal peptide is removed. For this study, we
used a cytoplasmic derivative of MBP called MBP2, which
differs from the mature MBP protein in that it has a
methionine at the N terminus in place of the signal peptide,
and the last four residues are replaced by a 20-residue-
engineered linker and residues encoded by a MCS on the
pMAL vectors. We used error-prone PCR to create mutant
alleles of the gene that encodes MBP2 and screened about
4,000 isolates from two independent libraries of MBP2
mutants. Among the 19 mutations obtained, we identified
substitutions at 14 positions in the amino acid sequence and
one frameshift mutation. The frameshift was in the last base
of the malE gene present in our construct and affected the
residues that are encoded by the engineered linker. Many of
the mutants contained multiple mutations. We separated the
mutations and tested them individually to identify which of
the mutations were responsible for the increase in yield from
the affinity purification relative to MBP2 (high-yield pheno-
type). In all cases but two, we found that a single mutation
could account for the high yield of the original mutant (data
not shown). However, we cannot rule out that the additional
mutations that have no phenotype when tested alone could
contribute to the phenotype of the original mutant. In the two
cases where more than one mutation contributed to the
phenotype, we found other variants of MBP2 that contained
justone ofeachofthechanges.Thelocations ofthemutations
in the primary sequence are shown in Fig. 1,w h i l eF i g .2
shows a cartoon of the structure of MBP and the location of
the residues mutated. All but one of the mutations are located
between residues 68 and 115 in the N-terminal half of the
sequence and between residues 303 and 343 in the C-
terminal half; the final mutation, the Δ2682 deletion, creates
a frameshift which affects residues from 367 to the end.
There is a hotspot for mutations in helix 14 of domain I,
which contains a number of residues that interact with
domain II in the open conformation (Marvin and Hellinga
2001a; Telmer and Shilton 2003).
Effect of mutations on affinity purification of MBP2 and a
fusion derivative After the initial identification of the
mutations, we retested each MBP2 derivative in a 1-mL
column format. In order to test whether the increased yield
of MBP2 would carry over to problematic fusion proteins,
we also constructed pMAL vectors that would express an
MBP2-chitin binding domain fusion (MBP2-CBD) for each
of the mutations. Under the conditions we used, approxi-
mately 95% of the wild-type derivatives of both MBP2 and
MBP2-CBD failed to bind or prematurely eluted from the
amylose resin during the wash. The yield for wild-type
MBP2 in these experiments was 2.3±0.85 mg/L; the yield
for wild-type MBP2-CBD was 3.7±1.1 mg/L (average of
19 experiments; error is the 95% confidence interval). All
19 mutations were tested as MBP2 and MBP2-CBD
fusions, and the results are shown in Fig. 3a. The mutations
increased the yield of MBP2 from 1.3- to 15-fold over
wild-type MBP2. With the exception of V302L, Y307C,
and M321K, the mutations that led to an increase in MBP2
yield also led to an increase MBP2-CBD yield; unlike the
V302L derivative, the V302A derivative of MBP2-CBD
did give an increased yield.
Mutations that retain the solubility enhancement properties
of MBP fusions In order to see if the mutations affected the
ability of MBP2 to enhance the solubility of fused proteins,
we constructed pMAL plasmids that expressed MBP2 fused
to human dihydrofolate reductase (MBP2-DHFR) for each
of the mutations. We chose DHFR from among the proteins
whose solubility had previously been shown to be enhanced
by MBP (Kapust and Waugh 1999). Figure 3b shows the
results of this solubility assay. Five out of the 19 mutations
retain all or most of the solubility enhancement property of
MBP2 for this fusion: F67L, A312V, I317V, Q325R, and
V343M. To test if the solubility-enhancement properties of
these five mutations might extend to other proteins, we
tested them as fusions to murine glyceraldehyde phosphate
dehydrogenase (MBP-GAPDH), another protein whose
solubility has been shown to be enhanced by MBP (Kapust
and Waugh 1999). All of these mutations, with the possible
exception of Q325R, were able to solubilize GAPDH about
as well as wild-type MBP2 (Fig. 3b).
Combinations of mutations We made one class of double
mutants to test whether the loss of solubility enhancement
due to a change in one residue could be rescued by a
second mutation, by testing the solubility of MBP2-DHFR
derivatives with the A312V mutation along with substitutions
at N323 and N332. The original mutations at these residues,
N323Y and N332I, reduced the solubility of MBP2-DHFR,
while A312V was neutral or slightly increased its solubility.
Wereasonedthatanotherhydrophilicsidechainasasubstitute
for asparagine would be more likely to retain solubility
enhancement, and the addition of A312V might provide some
additional increase in the solubility properties of the mutant.
190 Appl Microbiol Biotechnol (2010) 88:187–197Fig. 1 Sequence of MBP2 and location of mutations. Mutations are
indicated in bold under the amino acid sequence. Δ2682 indicates a
deletion of a thymine at position 2682 in the DNA sequence, which
leads to a frameshift of the subsequent residues in MBP2. Secondary
structural elements are indicated above the sequence, arrows for β-
sheets and helices for α-helices, according to the PDB file 1ANF
(Spurlino et al. 1991). The β-sheets are labeled with a letter to
indicate the structural element and a number to indicate the strand in
that element; e.g., β-sheet “A” is made up of two strands, A1 and A2.
Helices are indicated by a number. The numbering of the mutations
we obtained ignores the N-terminal methionine present in MBP2, to
simplify comparison to the structure and the previous literature. The
sequences corresponding to the hinges between the two domains are
indicated as bold letters embedded in the sequence
A
B
Fig. 2 MBP structure and
location of mutated residues.
Structure from PDB file 1ANF
rendered using PyMOL.
Domain I is in green, domain II
is in yellow, hinge regions are
in cyan, and maltose carbons
are in salmon. View is from
the opposite side from the
binding cleft. a Cartoon of MBP
structure. b Location of mutated
residues. Stereo view of the
α-carbon trace of MBP, with
the residues where mutants
were obtained in crimson
Appl Microbiol Biotechnol (2010) 88:187–197 191Thus, we tested the double mutants A312V N323Q, A312V
N323R,A312VN332Q,andA312VN332R.Allfourofthese
mutants had a greatly reduced ability to solubilize the fused
DHFR compared to wild-type MBP2, one fifth that of wild-
type or less (data not shown).
We constructed another class of double mutants to see if
two mutations that individually provided good solubility
could be combined to produce a double mutant that retained
the solubility property while also maintaining increased
affinity. The double mutants we constructed were A312V
I317V, A312V I317A, A312V Q325R, and A312V Q325K.
The results are shown on Table 1. The A312V Q325X
mutants showed reduced ability to enhance the solubility of
DHFR compared to wild-type, but the A312V I317V and
A312V I317A mutants had solubility properties at least
equal to wild-type. Encouraged by these results, we tested
the double mutants for their yield of MBP2 and MBP2-
CBD in the amylose affinity purification. Both the A312V
I317Vand, to a lesser degree, the A312V I317A mutant gave
increased yields in the affinity purification compared to wild-
typeforboththeMBP2andMBP2-CBDderivatives(Table1).
Dissociation constants for MBP mutants We measured the
affinity for maltose and maltotriose for each mutant MBP
that retained the ability to enhance the solubility of DHFR.
The method we used was ligand-induced fluorescence
quenching of tryptophan, essentially as described (Miller
et al. 1983). Emission wavelength scans were performed for
each mutant, and we discovered that the shape of the curves
for the MBP2 derivatives we tested was slightly different
from that described in the literature for MBP (Fig. S2). For
fluorescence quenching with maltose, we chose an emission
wavelength of 350 nm. For fluorescence quenching with
maltotriose, we used either 330 and/or 350 nm, depending
on the shape of the emission spectrum. In cases where both
330 and 350 nm titrations were done, the results were in
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Fig. 3 a Yield of MBP2 and
MBP2-CBD derivatives. MBP2,
MBP2-CBD, and their mutant
derivatives were purified on a
1-mL amylose column as
described in “Materials and
methods” and the results graphed
as the yield of protein relative to
the yield of wild-type MBP2 in a
purification performed in paral-
lel. Values for wild-type MBP2
and A312Vare the average of 19
experiments (included as controls
in all experiments); values for
the remaining mutants are the
average of 2–8e x p e r i m e n t s .
Error bars are 95% confidence
intervals. b Cells expressing
MBP2-DHFR or MBP2-GAPDH
and their mutant derivatives were
lysed and fractionated into solu-
ble and insoluble fractions, and
the amount of soluble and
insoluble fusion protein was
quantitated, as described in
“Materials and methods.” Results
are expressed as the ratio of
soluble MBP fusion protein to
total MBP fusion protein. Values
for wild-type and A312V are the
average of 19 and 16 experi-
ments, respectively (included
as controls in all or most experi-
ments, respectively); all others
are the average of three to four
experiments and are expressed as
% soluble relative to wild-type
in the same experiment, then
normalized to the overall wild-
type average. Error bars are
95% confidence intervals
192 Appl Microbiol Biotechnol (2010) 88:187–197good agreement. We determined the dissociation constants
using curve-fitting software with the standard equilibrium
equation as the model. The results are given in Table 2.I n
most cases, those mutants that show an increased yield in
the affinity purification also show a decrease in the Kd. The
exceptions are F67L, where the Kds for both maltose and
maltotriose are increased relative to MBP2, and V343M,
where the Kd for maltotriose is increased. We presume that
the Kd for maltotriose is more relevant, since the amylose
column is derivatized with maltodextrins of chain length
greater than three.
Discussion
Using random mutagenesis of the sequence encoding the
MBP2 protein, we were able to find mutations in MBP2 that
enhanceitsyieldinanaffinitypurification.Nineteenoutofthe
4,000 mutants screened, orabout 0.5%, showed anincreasein
yield in a microscale amylose resin affinity purification. The
distribution of the mutations was nonrandom, with six
mutations clustered between residues 64 and 115 in the N-
terminal half of the protein, and the remaining 13 mutations
clusteredbetweenresidues303and367intheC-terminalhalf.
We obtained multiple isolates where the same residue was
mutated, suggesting that we had isolated mutations in most of
the residues that could be obtained using this method of
mutagenesis and screening.
Models for altered affinity Thereareanumberofmodelsthat
could explain the increased binding of our MBP mutants. The
previous work has focused on the fact that the open
conformation of MBP is stabilized by a large area of contact
between the two domains behind the hinge (Marvin and
Hellinga 2001a; Telmer and Shilton 2003). In the maltose-
bound closed form, the corresponding areas of this interface
are solvent-exposed. Alterations of MBP that disturb the
interface alter the equilibrium toward the closed form, and
affinity for maltodextrins is increased, since the energetic
penalty for separating the interface is reduced or eliminated.
One could also imagine that alterations that change the
geometry of the hinge loops could alter the equilibrium
between the open and closed conformations in a similar
manner. Another way to affect ligand binding might be to
alter the binding site, by mutating residues that form contacts
to the ligand, or indirectly, by making nearby changes that
move those residues slightly. Finally, MBP makes extensive
contacts to the MalFGK transporter as it docks and releases
its ligand, especially between domain I of MBP and the P2
loop of MalF (Oldham et al. 2007). It is possible that these
contacts induce a conformational change in MBP to reduce
its affinity for the ligand, and mutations in MBP that disfavor
this hypothetical shift might increase its affinity.
Mutations that affect the interface behind the hinge Several
of our mutations, located between residues 300 and 330,
can be rationalized by reference to the previous site-
directed work and fit the model that biasing the conforma-
tional equilibrium towards the closed form increases MBP’s
affinity for maltodextrins. This region includes residues that
were modified by Hellinga’s lab (I329) and Shilton’s lab
(M321 and Q325). In fact, we obtained mutations in the
latter two residues in our screen. These mutations interfere
with the packing of the interface between the two domains
Table 1 Solubility and yields of double mutants Solubility was calculated as in Fig. 3
MBP2 derivative % MBP2-DHFR soluble MBP2 yield (mg/L) MBP2-CBD yield (mg/L)
wt 62% 2.3±0.5 3.5±0.9
A312V I317V 67% 31±4.8 44±3.1
A312V I317A 74% 16±3.9 22±4.1
A312V Q325R 35% ND ND
A312V Q325K 35% ND ND
For solubility, the value for wt is the average of 19 experiments, and the values for the mutants are from two to three experiments. For yields, the
value for wt is from 19 experiments, and the values for the mutants are the average of six experiments; errors indicate the 95% confidence interval
ND not determined
Table 2 Dissociation constants of a subset of the mutant proteins
Kd maltose Kd maltotriose
MBP2 1.49±.01 0.38±.02
F67L 7.00±.7 1.40±.2
A312V 0.23±.02 0.11±.01
I317V 0.60±.08 0.20±.03
Q325R 0.52±.05 0.31±.02
V343M 0.92±.06 0.54±.05
A312V I317V 0.16±.02 0.03±.01
A312V I317A 0.86±.06 0.19±.03
Values are calculated as described in “Materials and methods”; error is
calculated from the curve-fitting software, and is not an experimental
error
Appl Microbiol Biotechnol (2010) 88:187–197 193that forms when MBP is in the open conformation. We
predict that our mutation in A318 also falls in this category,
and probably T93A, V302A, V302L, Y307C, N323Y, and
N332I as well (Fig. 4). The T93 side chain is not part of the
interface itself but rather is on the opposite side of helix 5
from F92, which makes van der Waals contacts with
domain II in the open conformation. Likewise, the A302,
Y307, N323 side chains are on the opposite sides of helix
13 and 14 that form part of the domain II surface of the
interface. The K83R mutation does not offer an analogous
rationale, but the K83 side chain undergoes an extensive
remodeling during the open to closed transition, and it is
possible that the arginine substitution has effects on the
position of helix 5 as well. The side chain of N332 forms a
link between the two domains by hydrogen bonding to the
backbone carbonyl of A96 in the closed conformation and
flexes with domain II as the conformation opens. While not
directly part of the interface that forms as the conformation
shifts to the open form, this hydrogen bond provides a unique
way for domains I and II to communicate independent of the
hinge regions, by linking the hinge motion to an alteration of
the conformation of the loop between helices 14 and 15. It
might be possible to test whether these mutations affect the
equilibrium between the open and closed forms. NMR
experiments using paramagnetic relaxation enhancement
(PRE) have shown that in the absence of maltose, MBP exists
as a rapidly exchanging mixture of ∼95% open and ∼5%
closed form (Tang et al. 2007). Using this technique on the
mutant MBPs would allow one to measure the equilibrium
between the open and closed forms directly.
Mutations that affect the hinge Several of our mutations are
located in or directly adjacent to two of the hinge regions
between domains I and II. The mutations V110I and S114L
are in or near hinge region 1 (residues 110–113), and
A312V and I317V are in or near hinge region 3 (residues
311–315). These mutations could also indirectly affect the
packing of the interface behind the hinge, or they could
affect the conformation of the hinge directly and thus alter the
equilibrium between the open and closed conformations. The
A312V and I317V mutations in particular suggest the latter
possibility, as the A312 side chain is solvent exposed in the
open conformation but rotates inward and forms van der
Waals contacts with I317 in the closed conformation (Fig. 5).
Fig. 4 Residueswheremutations
may affect packing behind the
hinge. a Cartoon of MBP
showing residues where
mutations were obtained. Colors
as in Fig. 2, except labeled
residues in red. b Surface
representation of MBP in the
closed conformation; colors as
in (a). c Surface representation of
MBP in the open conformation;
colors as in (a)
194 Appl Microbiol Biotechnol (2010) 88:187–197Again, NMR PRE experiments would allow one to assess
directly the effect of the mutations on the conformational
equilibrium.
Mutations away from the interface and hinge The A63V,
F67L, V343M, and ΔT2628 mutations are located farther
from the hinges and the interface behind the hinges than the
other mutations, suggesting a different mode of action. The
A63V, F67L, and V343M mutations are adjacent to
residues that form hydrogen bonds to the bound maltose,
making it possible that they affect the binding pocket
(Fig. 6). A63 is adjacent to W62, which forms a hydrogen
bond to the bound maltose. F67 is on the face of helix 3
opposite to D65 and R66, which both also form hydrogen
bonds to maltose. V343 forms van der Waals contacts with
P154, which is adjacent to E153 and on the opposite face of
helix 7 from Y155. E153 forms a hydrogen bond to maltose
and the ring of Y155 stacks with the bound sugar. Paradox-
ically,the A63VandV343Mmutations causeMBP2tohavea
lower affinity for maltotriose, at least under the conditions
used to measure affinity in this study. It is possible that these
mutations have some effect on the kinetics of binding, for
example, disproportionately decreasing the off rate of the
ligand. However, we performed the Kd measurements under
low ionic strength conditions (for comparison to values in the
literature), as opposed to the moderate ionic strength we used
in the affinity purification. Interestingly, the V343M mutation
lies inside a subdomain consisting of residues 165 to183 and
334 to 369, which has been identified as the part of MBP that
varies in position when binding maltose vs. longer maltodex-
trins (Quiochoetal. 1997). Measuring Kds under a variety of
E153
V343
P154
Y155
H15
H7
F67
A63
W62
D65
R66
H3
A
B
Fig. 6 Location of mutationsnearthe maltosebinding site. Colors are as
in Fig. 3, with hydrogen bonds indicated as heavy dotted lines,a n dlight
dotted lines indicating stacking interactions. a A63 and F67. b V343
Fig. 5 Position of A312 and I317. a Open (unliganded) conformation,
PDB 1JW4 (Duan and Quiocho 2002). b Closed (maltose bound)
conformation
Appl Microbiol Biotechnol (2010) 88:187–197 195conditions and increasing the number of forms of maltodextrin
tested might clarify the effects of thesemutations. TheΔT2628
mutation is a frameshift mutation that changes all the residues
encoded by the synthetic linker following the portion of the
malE gene used in this construct. Because of the large number
of substitutions caused by this mutation, it will require quite a
bit of further study to determine which of these substitutions
affect the yield and solubility of MBP2 fusions.
Effects on solubility enhancement Most of the mutations
we obtained reduce the ability of MBP2 to enhance the
solubility of an MBP2–DHFR fusion protein. From the
wide variety of mutations that have this behavior, it seems
that this property of MBP2 is somewhat sensitive to
alteration. These mutations did not cause MBP2 itself to
become insoluble, as the mutant MBP2s had to have
reasonable solubility to pass the screen for increased yield
in the affinity purification. Fox et al. identified substitutions
of glutamate for W232, Y242, and I317 as defective in
enhancing the solubility of three aggregation-prone proteins
fused to MBP (Fox et al. 2001). These residues are all
located at one end of the maltodextrin-binding cleft,
potentially defining a site involved in enhancing solubility.
However, the mutations in these residues all showed
reduced stability as well, which led these researchers to
conclude that it could also be some global defect in the
folding of MBP that reduced the solubility enhancement.
Our widely scattered mutations with the same property of
reduced solubility enhancement only confuse the issue
further, since they do not fit the model of a site on the
surface of MBP that is important for this property. In fact,
unlike the I317E mutation of Fox et al., our substitutions of
valine and alanine for I317 did not reduce solubility
enhancement. We think it is more likely that some of the
mutations create disruptions of the folding pathway or
possibly in the form or lifetime of a folding intermediate,
which also disrupt the interaction between MBP and the
protein to which it is fused.
MBP mutants as fusion tags Mutations that increase the yield
from the amylose affinity purification and retain the ability of
wild-typeMBPtoenhance thesolubilityofaggregation-prone
proteins have obvious utility as potential fusion tags. Five of
the 19 mutations retained the solubility enhancement seen
with the MBP2-DHFR fusion. Three of these, A312V, I317V,
and Q325R, have higher affinity for maltodextrins, most
likely caused by shifting the equilibrium of MBP towards the
closed conformation as discussed above. The reason for the
increased yield of MBP2 fusions containing F67L and
V343M is more obscure, although the F67 and V343 residues
are located adjacent to residues that form bonds to the bound
maltodextrin. The double mutants A312V I317V, and A312V
I317A show an even higher affinity while maintaining
solubility enhancement. The increased yield of these MBP
derivatives when purified on immobilized amylose translates
to an increase in yield of at least one fusion protein, the MBP-
CBD fusion. Butitisnot clear thatall MBP fusions thatfailto
bind to amylose do so in the same way. One can imagine that
one mode offailure could be aninteraction between MBP and
the fused protein that alters the conformation of MBP. In this
case, alterations that bias MBP towards the closed form may
improve the binding of the fusion. However, another mode of
failure might be misfolding of the fused protein, leading to a
nonspecific interaction with the hydrophobic binding cleft of
MBPthatblocksaccesstothe bindingsite.Inthiscase,higher
binding affinity might not lead to improved binding of the
fusionprotein.Futureworkwillshowhowmuchthese mutant
MBPs withincreased affinitywillimprove the success ratefor
purifyingfusionproteinsbyamyloseaffinitychromatography.
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